VestGen Advisors’s United Therapeutics UTHR Stock Holding History

VestGen Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$472K	Buy	872 +292	+50%	+$164K	0.01%	688
2026 Q1	$337K	Buy	+580	New	+$289K	0.01%	801

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

VestGen Advisors's UTHR Position: Q2 2026 in Review

VestGen Advisors increased its United Therapeutics (UTHR) stake by 50% in Q2 2026, buying an estimated $164K and bringing the position to 872 shares worth $472K. The position accounts for 0.01% of the portfolio, ranked #688.

VestGen Advisors first reported a position in UTHR in Q1 2026 and has held it in 2 quarters since. 882 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

VestGen Advisors held 872 shares of United Therapeutics worth $472K as of Q2 2026.
VestGen Advisors bought 292 United Therapeutics shares in Q2 2026, an estimated $164K.
United Therapeutics made up 0.01% of VestGen Advisors's portfolio in Q2 2026, its #688 holding.
VestGen Advisors first reported a position in United Therapeutics in Q1 2026 and has held it in 2 quarters since.
882 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on VestGen Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.